|
Research article summary:
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinsons disease: a randomised, placebo controlled, double blind, six month study.
Abstract Extract:
OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinsons disease with both fluctuating and non-fluctuating response to ... (Full abstract text below) Published 2003Aug
in Journal: J Neurol Neurosurg Psychiatry
(Language : eng)
Full Pubmed Extract
This information was retrieved, real-time, on your behalf from the public area of the Pubmed website:
1. J Neurol Neurosurg Psychiatry.
2003 Aug;74(8):1071-9
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
Brooks DJ, Sagar H,
Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. david.brooks@csc.mrc.ac.uk
OBJECTIVE: To study the effect of entacapone, a specific peripherally acting catechol-O-methyltransferase (COMT) inhibitor used in combination with levodopa treatment, in cases of Parkinson's disease with both fluctuating and non-fluctuating response to treatment. METHODS: A randomised, placebo controlled, double blind, six month study was undertaken in 172 fluctuating and 128 non-fluctuating patients. The clinical efficacy and safety of 200 mg entacapone given with each daily levodopa dose was studied. Efficacy was examined using home diaries, the unified Parkinson disease rating scale (UPDRS), and recording of daily levodopa dose. RESULTS: The primary efficacy variable for fluctuating patients-the proportion of daily ON time-showed a significant increase compared with placebo (p < 0.05). The absolute ON time (mean (SD)) increased from 9.5 (2.5) to 10.8 (2.4) hours (p < 0.01), and the daily OFF time was correspondingly reduced from 7.0 (2.6) to 5.9 (2.5) hours (p < 0.05 v placebo). This improvement was achieved despite a reduction in daily levodopa requirements. The effect was rapidly lost on withdrawal of entacapone. In non-fluctuating patients, the primary efficacy measure was part II of the UPDRS (activities of daily living; ADL). In this group of patients, ADL scores improved in the entacapone group (p < 0.01 v placebo), and there was also a 40 mg reduction in levodopa requirement (p < 0.01 v placebo). Entacapone was well tolerated by both fluctuating and non-fluctuating patients. CONCLUSIONS: The ability of entacapone to provide additional benefits to levodopa treatment in increasing ON time in fluctuating Parkinson's disease patients was confirmed. A novel finding was that patients without fluctuations also obtained benefit from the addition of entacapone to their levodopa treatment, as evidenced by improved ADL scores and a relatively reduced levodopa requirement.
PMID : 12876237 [PubMed - Indexed for MEDLINE]
This information is obtained from the National Library of Medicine (NLM). Abstract text and other information may be subject to copyright. Type "NLM copyright" into Google for more information.
Full Author Information
| First Name | LastName | Initials |
| D J | Brooks | DJ |
| H | Sagar | H |
| | |
Affiliation: Division of Neuroscience, Faculty of Medicine, Imperial College, Hammersmith Hospital, Du Cane Road, London W12 0NN, UK. david.brooks@csc.mrc.ac.uk
3rd Party provider links
Click the links below to go to related 3rd party information:
MESH categories and related page links
This article was linked to the MESH categories shown on the left below. The links on the right are related Memletics pages.
Category links from this article:- Activities of Daily Living - classification
- Aged
- Antiparkinson Agents - administration & dosage, adverse effects
- Catechol O-Methyltransferase - antagonists & inhibitors
- Catechols - administration & dosage, adverse effects
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy, Combination
- Enzyme Inhibitors - administration & dosage, adverse effects
- Female
- Humans
- Levodopa - administration & dosage, adverse effects
- Male
- Middle Aged
- Motor Skills - drug effects
- Neurologic Examination - drug effects
- Nitriles
- Parkinson Disease - diagnosis, drug therapy
| | Related Memletics topics: |
Links for this articleFor links to places where you can get the full text of this article see links. Note there may be a subscription or fee required for access to the full text. New! Using similar technology to this site, we have launched find-health-articles.com, targeting over 1 million health research article abstracts. Related ArticlesHere are some articles related to this one (by title keywords): Keywords in this article:ability, absolute, achieved, acting, activities, additional, adl, benefits, blind, cases, catechol, clinical, combination, compared, comt, conclusions, confirmed, controlled, correspondingly, daily, despite, diaries, disease, dose, double, effect, efficacy, entacapone, evidenced, examined, finding, fluctuating, fluctuations, given, group, home, hours, ii, improved, improvement, increase, increased, increasing, inhibitor, levodopa, living, lost, mean, measure, methods, methyltransferase, month, non, novel, objective, off, parkinson, part, patients, peripherally, placebo, primary, proportion, provide, randomised, rapidly, rating, recording, reduced, reduction, relatively, requirements, response, results, safety, scale, scores, sd, significant, six, specific, studied, study, time, tolerated, treatment, undertaken, unified, updrs, variable, well, withdrawal
|
